The redesigned website reflects IDD’s commitment to providing high-end, tailored solutions across the entire drug value chain. Key features of the new site include:
- In-depth service descriptions: A clear overview of IDD’s core services, including asset pre-approval, medicines post-approval, and business platform services.
- Streamlined navigation: An intuitive design that makes it easy for visitors to find the information they need.
- Modern and responsive design: A seamless experience across all devices.
“We are thrilled to launch our new website and provide our clients and partners with a more engaging and informative online experience,”.
“This new site is a testament to our ongoing commitment to excellence and innovation in the pharmaceutical consulting industry.”
The new website will be regularly updated with news, insights, and company updates. Visitors are encouraged to explore the site and learn more about IDD’s services.
First, Clarisse Ribeiro, who joined in MM/2025, holds a degree in [to be completed], and specializes in [to be completed].
Next, Mohamed ALILI, a Doctor of Pharmacy since 2020 in Algeria, is currently completing an internship to validate his degree in France. He is involved in Quality Assurance and Regulatory Affairs under the direct supervision of Anne Walter.
Finally, we welcomed a second intern in May 2025. Swann Walch is completing his fifth-year pharmacy internship under the supervision of Stéphane Simon, contributing to business development and the integration of AI into company processes.
These new additions reflect the energy and momentum of both companies, their appeal to young talent, and their commitment to excellence, innovation, and knowledge sharing.
2024 ended on a high note with the celebration of IDD’s 20th anniversary alongside our valued partners and clients. This milestone was made possible thanks to the dedication and expertise of our team members, the true driving force behind our achievements.
In 2025, we look forward to continuing our collaboration on your development plans, regulatory challenges, and business operations. May this year bring fruitful partnerships, growth, and exciting new opportunities.
Stéphane Simon joins as VP, Chief Pharmaceutical Officer of IDD and CEO of Bio Valys Pharma. With 30 years of experience as a Qualified Person and a strong background in regulatory leadership, he will lead the development of a new strategic pillar focused on pharmaceutical commercialization.
Anne Walter takes on the role of Director of Pharmaceutical Affairs & Exploitation. With over three decades of experience in quality, pharmacovigilance, and compliance, she will strengthen IDD’s regulatory foundations and help shape its future strategic offerings.
Their appointments represent a significant milestone in IDD’s growth, reinforcing our expertise and expanding our capabilities for the years ahead.